anthonyyazdaniml/CT-ADE-SOC huggingface dataset:
Intervention: Alfentanil
Trial phase: Phase 4
ATC code: N01AH02
SMILES: CCC(=O)N(c1ccccc1)C1(COC)CCN(CCn2nnn(CC)c2=O)CC1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 87
Group description: Alfentanil: Administration of alfentanil during the induction and maintenance of anesthesia for electroconvulsive therapy to be performed
Eligibility criteria:
Inclusion Criteria:

Age > /=18 years
Males or females
Anticipating electroconvulsive therapy to treat refractory depressive disorder

Exclusion Criteria:

Under the age of 18
Allergy to alfentanil
Allergy to other standard anesthetic medications utilized in the course of ECT (glycopyrrolate, methohexital, and succinylcholine)
History of malignant hyperthermia
History of severe airway obstruction, bronchospasm or laryngospasm
History of recent myocardial infarction, ventricular arrhythmia
Adverse reaction to ECT requiring premedication with lidocaine or atropine
Non-English speaking
Patients unable to consent for themselves
Current pregnancy
Intervention: Sitagliptin
Trial phase: Phase 2
ATC code: A10BD07 | A10BD12 | A10BD24 | A10BH01 | A10BH51
SMILES: N[C@@H](CC(=O)N1CCn2c(nnc2C(F)(F)F)C1)Cc1cc(F)c(F)cc1F
Sex: All
Age groups: Adult
Healthy volunteers: No
Participants at risk: 17
Group description: Drug: Sitagliptin

The treatment consists of sitagliptin 100 mg/day up to a maximum of 24 weeks.
Eligibility criteria:
Inclusion Criteria:

Male or female subject with diabetes mellitus type 2.
Age between 18 and 64 years, both inclusive.
HbA1c <= 8.5%.
Stable treatment with insulin glargine (any dose) and metformin (>= 1500 mg/day or at highest tolerated dose) for at least 3 months prior to inclusion into the trial with or without additional oral glucose-lowering agents (except thiazolidinediones).
Considered generally healthy (apart from diabetes mellitus type 2 and associated conditions such as hypertension, hyperlipidaemia and hyperuricaemia) upon completion of medical history, physical examination, vital signs, ECG and analysis of laboratory safety variables, as judged by the Investigator.

Exclusion Criteria:

Known or suspected hypersensitivity to sitagliptin or related products.
More than one episode of severe hypoglycaemia with seizure, coma or requiring medical assistance of another person during the past 6 months or hypoglycaemic unawareness as judged by the Investigator.
Current or previous treatment (less than 3 months prior to screening) with insulin products other than insulin glargine and/or with Glucagon-like peptide (GLP) 1 receptor agonists and/or with thiazolidinediones.
Unwillingness to wash-off any oral glucose-lowering agents other than metformin.
Intervention: Caffeine
Trial phase: Phase 4
ATC code: D11AX26 | N06BC01 | R03DA20 | V04CG30
SMILES: Cn1c(=O)c2c(ncn2C)n(C)c1=O
Sex: Male
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 8
Group description: Participants received a caffiene infusion
Eligibility criteria:
Inclusion Criteria:

Age 25-40.
Male.
Normal healthy subject without systematic diseases or conditions.
Metabolic Equivalents of Functional Capacity >= 5.
Low risk for Obstructive Sleep Apnea (OSA) based on the screening test (STOP-bang score established by American Society of Sleep Apnea): Yes to > 3 items- high risk of OSA
No History of Arrhythmia (Baseline EKG will be obtained during the history and physical session), seizure, liver and kidney diseases.
BMI < 30 kg/m2.
No history of prior difficulty with anesthesia.
No personal or family history of malignant hyperthermia.
No history of any mental illness.
No history of drugs or alcohol abuse (urine drug screens required).
Subjects capable of giving consent.
Living less than 30 miles away from University of Chicago.
No history of seizure disorders.
No history of head trauma.

Exclusion Criteria:

Age <25 or >40.
Female.
ASA physical status > 1 (normal healthy subject without systematic diseases or conditions)
Metabolic Equivalents of Functional Capacity (METs) < 5.
High risks for Obstructive Sleep Apnea (OSA) based on the screening test (STOP-bang score established by American Society of Sleep Apnea): Yes to > 3 items- high risk of OSA
History Arrhythmia (Baseline EKG will be obtained during the history and physical session), seizure, liver and kidney diseases
BMI>30 kg/m2.
Prior difficulty with anesthesia.
Personal or family history of malignant hyperthermia.
History of any mental illness.
History of drugs or alcohol abuse (urine drug screens required)
Subjects not capable of giving consent
Living more than 30 miles away from University of Chicago.
History of seizure disorders.
History of head trauma.
Intervention: Propofol
Trial phase: Phase 4
ATC code: N01AX10
SMILES: CC(C)c1cccc(C(C)C)c1O
Sex: All
Age groups: Adult
Healthy volunteers: Accepts Healthy Volunteers
Participants at risk: 30
Group description: Propofol: Propofol administration
Eligibility criteria:
Inclusion Criteria:

Must have a body mass index (BMI) less than 30.
Must be right handed
Must be English speaking
Must be capable of giving written informed consent.
Must have history of playing tennis (or any type of racquet sport) at least 30 times over lifetime.

Exclusion Criteria:

History of obstructive sleep apnea;
History of a difficult airway with a previous anesthetic;
History of neurological disorders;
Hypertension or other cardiovascular abnormalities;
Pulmonary hypertension or other pulmonary abnormalities;
Gastroesophageal reflux disease (GERD) or heartburn;
History of significant head injury with loss of consciousness;
Learning disability or other developmental disorder;
Allergic reactions to eggs;
Pregnant or nursing mothers;
Contraindications to neuroimaging methods;
Inability or unwilling to fast, or withhold food and liquid intake, for 8 hours prior to your scheduled study visit.
Unwilling to abstain from alcohol use for 24 hours prior to your scheduled study visit.
History of drug use, or have a positive drug screen.
Tattoos on the head or neck region - all other tattoos are subject to determination by investigators.
Any impairment, activity or situation that in the judgment of the study coordinator or Principal Investigators would prevent satisfactory completion of the study protocol.
Intervention: Furosemide
Trial phase: Phase 2
ATC code: C03CA01 | C03CB01 | C03EB01 | G01AE10
SMILES: NS(=O)(=O)c1cc(C(=O)O)c(NCc2ccco2)cc1Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 9
Group description: Furosemide: furosemide
Eligibility criteria:
Inclusion Criteria:

Patients with chronic rhinosinusitis and sinonasal polyposis who are candidates for functional endoscopic sinus surgery

Exclusion Criteria:

Hypersensitivity to furosemide or sulfonamides
pregnancy
history of tinnitus
history of sensorineural hearing loss
poorly controlled diabetes
current diuretic therapy
known electrolyte disorder
currently taking aminoglycosides
BUN and creatinine levels out of the normal range
history of renal disease
allergy to sulfonamides
Intervention: Sodium tetradecyl sulfate
Trial phase: Not Applicable
ATC code: C05BB04
SMILES: CCCCC(CC)CCC(CC(C)C)OS(=O)(=O)[O-].[Na+]
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 12
Group description: Participants were randomized to either compression stockings or perforator vein injection with sodium tetradecyl sulfate, plus compression stockings.
Eligibility criteria:
Inclusion Criteria:

• The subject must be > 18 years of age, male or female

Subject must be willing and able to wear compression stockings
Subject must have refluxing perforating veins ≥ 3.0 mm in diameter at the calf level or distally in the affected leg.
Subject presents with ulceration or other symptoms of venous stasis including:

rash, swelling, pain, bleeding, recurrent cellulitis

• The subject must sign a written informed consent, prior to randomization, using a form that is approved by the local Institutional Review Board.

Exclusion Criteria:

• Pregnancy

Known allergy to STS
Refusal to wear compression stocking
Untreated significant great or small saphenous reflux
Disseminated malignancy or other terminal condition where subject is expected to live less than 6 months.
Significant arterial disease (ABI < .8)
Buergers disease
Acute superficial thrombophlebitis
Phlebitis migrans
Acute cellulitis
Clinical evidence of active local or systemic infection
Intervention: Cladribine
Trial phase: Phase 4
ATC code: L01BB04 | L04AA40
SMILES: Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 270
Group description: Participants received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year.
Eligibility criteria:
Inclusion Criteria:

Highly active RMS as defined by:
One relapse in the previous year and at least 1 T1 Gadolinium (Gd)+ lesion or 9 or more T2 lesions, while on therapy with other disease modifying drugs (DMDs)
Two or more relapses in the previous year, whether on DMD treatment or not.
Expanded Disability Status Scale (EDSS) score less than equals to (<=) 5.0.
Other protocol defined inclusion criteria could apply.

Exclusion Criteria:

Previous exposure to drugs such as fingolimod, natalizumab, alemtuzumab, mitoxantrone and ocrelizumab.
Positive hepatitis C or hepatitis B surface antigen test and/or hepatits B core antibody test for immunoglobulin G (IgG) and/or immunoglobulin M (IgM).
Current or previous history of immune deficiency disorders including a positive human immunodeficiency virus (HIV) result.
Currently receiving immunosuppressive or myelosuppressive therapy with, for example, monoclonal antibodies, methotrexate, cyclophosphamide, cyclosporine or azathioprine, or chronic use of corticosteroids.
History of tuberculosis , presence of active tuberculosis, or latent tuberculosis
Evidence or suspect of Progressive Multifocal Leukoencephalopathy (PML) in Magnetic Resonance Imaging (MRI).
Active malignancy or history of malignancy.
Other protocol defined exclusion criteria could apply.
Intervention: Tyrosine
Trial phase: Phase 2
SMILES: N[C@@H](Cc1ccc(O)cc1)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 6
Group description: PET/CT Imaging with administration of [F-18] RGD-K5

PET/CT Imaging with [F-18] RGD-K5: PET Imaging/scan with [F-18] RGD-K5, PET Imaging/scan with RGD-K5, PET Imaging/scan with K5
Eligibility criteria:
Inclusion Criteria:

1. Patients presenting

a. to the neurologist for evaluation of stroke or TIA (Symptomatic) with: i. Symptomatic patients with plaque ≥70% in at least one carotid artery that would be implicated as the source of embolus responsible for the stroke/TIA. b. or to the vascular surgeon for CEA (Asymptomatic) with: i. asymptomatic patients with a luminal stenosis of ≥70% in at least one carotid artery (stable plaque) referred for CEA ii. age-matched by deciles to symptomatic patients

Exclusion Criteria:

stroke due to atrial fibrillation,
preexisting carotid stents in the artery of interest,
renal dysfunction defined as glomerular filtration rate (GFR) <40ml/min,
allergy to gadolinium based contrast agents,
Volunteers who have had four or more prior previous gadolinium contrast scans
metal implants incompatible with MRI or other condition that prohibits MRI,
pregnancy,
inability to provide informed consent and
age ≤18 years.
Intervention: Chloroprocaine
Trial phase: Phase 2
ATC code: N01BA04
SMILES: CCN(CC)CCOC(=O)c1ccc(N)cc1Cl
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 39
Group description: Chloroprocaine: A spinal anesthetic with 2% chloroprocaine (2cc or 40 mg) will be performed
Eligibility criteria:
Inclusion Criteria:

Patients scheduled for a knee arthroscopy that is anticipated to be less than one hour
Age 18 to 80 years
Ability to follow study protocol
English speaking

Exclusion Criteria:

Hepatic or renal insufficiency
Younger than 18 years old and older than 80
Allergy or intolerance to one of the study medications
Chronic gabapentin/pregabalin use (regular use for longer than 3 months)
Chronic opioid use (taking opioids for longer than 3 months)
Patients unable to undergo a spinal anesthetic or Laryngeal Mask Airway (LMA)/GA or patient refusal to spinal anesthesia or LMA/GA
Intervention: Mepivacaine
Trial phase: Phase 2
ATC code: N01BB03 | N01BB53
SMILES: Cc1cccc(C)c1NC(=O)C1CCCCN1C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 39
Group description: Mepivacaine: A spinal anesthetic with 1.5% Mepivacaine (3cc or 45 mg) will be performed
Eligibility criteria:
Inclusion Criteria:

Patients scheduled for a knee arthroscopy that is anticipated to be less than one hour
Age 18 to 80 years
Ability to follow study protocol
English speaking

Exclusion Criteria:

Hepatic or renal insufficiency
Younger than 18 years old and older than 80
Allergy or intolerance to one of the study medications
Chronic gabapentin/pregabalin use (regular use for longer than 3 months)
Chronic opioid use (taking opioids for longer than 3 months)
Patients unable to undergo a spinal anesthetic or Laryngeal Mask Airway (LMA)/GA or patient refusal to spinal anesthesia or LMA/GA
Intervention: Ciprofloxacin
Trial phase: Phase 4
ATC code: J01MA02 | J01RA10 | J01RA11 | J01RA12 | S01AE03 | S02AA15 | S03AA07
SMILES: O=C(O)c1cn(C2CC2)c2cc(N3CCNCC3)c(F)cc2c1=O
Sex: Female
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 250
Group description: Ciprofloxacin for the treatment of uncomplicated urinary tract infection

Ciprofloxacin: Ciprofloxacin 250 mg PO twice daily (BID) x 3 days for women with uUTI.
Eligibility criteria:
Inclusion Criteria:

Female patients ≥18 years of age with more than 24 hours of urinary symptoms attributable to a UTI
Two of the following signs and symptoms of uUTI: urinary frequency, urinary urgency, pain or burning on micturition, suprapubic pain, gross hematuria

A mid-stream urine specimen with:

a dipstick analysis positive for nitrite AND
a dipstick analysis positive for leukocyte esterase
Has given written informed consent to participate in the study.

Exclusion Criteria:

Presence of signs and symptoms suggestive of acute pyelonephritis: fever (temperature > 38°Celsius), chills, costovertebral angle tenderness, flank pain, nausea and/or vomiting
Receipt of prior effective antibacterial drug therapy for uUTI for the presenting illness unless the recovered pathogen demonstrates resistance to initial antibiotic and clinical symptoms persist
Concurrent use of non-study antibacterial drug therapy that would have a potential effect on outcome evaluations in patients with uUTI
Patients with ileal loops or urinary stoma
Patients with an indwelling urinary catheter in the previous 30 days
Patients with paraplegia
Patients who are likely to receive ongoing antibacterial drug prophylaxis after treatment of uUTI (e.g., patients with vesico-ureteral reflux)
Any history of trauma to the pelvis or urinary tract
Patient's urine culture results, if available at study entry, identify more than 2 microorganisms regardless of colony count or patient has a potential fungal pathogen
Patient's urine culture results, if available at study entry, identifies the causative uropathogen for the presenting illness to be resistant to ciprofloxacin
Patient has severe chronic kidney disease, or is receiving hemodialysis or peritoneal dialysis or had a renal transplant
Patient is known to have severe neutropenia
Patient is known to be pregnant
Patients with uncontrolled diabetes mellitus
Patients with a known history of myasthenia gravis
Patients who require concomitant administration of tizanidine
Patients with a history of allergy to quinolones
Patient is considered unlikely to survive the study period or has a rapidly progressive or terminal illness including septic shock which is associated with a high risk of mortality
Intervention: Flurbiprofen
Trial phase: Phase 2
ATC code: M01AE09 | M02AA19 | M02AA29 | R02AX01 | S01BC04
SMILES: CC(C(=O)O)c1ccc(-c2ccccc2)c(F)c1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 4
Group description: Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.

Plasma: Initial resuscitation with plasma will be 10 mL/kg (700 mL in a typical 70 kg adult). Traditional doses of plasma, when used to correct coagulopathy range from 10-15 mL/kg.23 The plasma will be administered at a rate of 2-3 mL/kg/hr (140-210 mL/hr in a typical 70 kg adult). A research physician will be at bedside to follow patient resuscitation. Plasma administration may be terminated before the entire dose is administered if patients show clinical improvement. After the initial dose of plasma has been given, subsequent resuscitation will follow usual care using balanced crystalloids.
Eligibility criteria:
Inclusion Criteria:

Patients meeting the following criteria will be enrolled: Have a Sepsis Screening Score (SSS) ≥ 4 with a suspected source of infection (Table 1); and Written informed consent obtained
Patients meeting any of the following criteria will be randomized: Hypotension with MAP < 65 mmHg; Lactic acid > 4 mmol/L; Altered mental status; and Decreased urine output of < 0.5 mL/kg in the past hour.

Exclusion Criteria:

Pregnancy
Prisoners
Traumatic brain injury
Evidence of ongoing hemorrhage, history of congenital bleeding disorders, therapeutic anticoagulation
History of myocardial infarction or congestive heart failure
History of acute cerebral vascular event
Major burns (>20% total body surface area)
History of adverse reactions to blood product transfusion
Contraindications to blood transfusions (eg. Jehovah's Witness)
Contraindications to central venous line and arterial line placement
On intermittent hemodialysis
Do-Not-Resuscitate or Comfort Care status
Participation in another interventional study
Pending transfer to another unit within the hospital that is not STICU or SIMU
Intervention: Cortrosyn
Trial phase: Phase 3
ATC code: H01AA02
SMILES: CSCCC(NC(=O)C(CO)NC(=O)C(Cc1ccc(O)cc1)NC(=O)C(N)CO)C(=O)NC(CCC(=O)O)C(=O)NC(Cc1c[nH]cn1)C(=O)NC(Cc1ccccc1)C(=O)NC(CCCNC(=N)N)C(=O)NC(Cc1c[nH]c2ccccc12)C(=O)NCC(=O)NC(CCCCN)C(=O)N1CCCC1C(=O)NC(C(=O)NCC(=O)NC(CCCCN)C(=O)NC(CCCCN)C(=O)NC(CCCNC(=N)N)C(=O)NC(CCCNC(=N)N)C(=O)N1CCCC1C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(Cc1ccc(O)cc1)C(=O)N1CCCC1C(=O)O)C(C)C)C(C)C)C(C)C
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 100
Group description: Administration of cortisol stimulation test to assess for presence or absence of adrenal insufficiency

Cosyntropin: Administer 250mcg cosyntropin to hospitalized cirrhosis patients to assess for the presence of adrenal insufficiency
Eligibility criteria:
Inclusion Criteria:

Age >=18 years
Diagnosis of cirrhosis
Admission to hospital

Exclusion Criteria:

Age < 18 years
Prior enrollment in study (i.e. readmission)
Prisoner
Pregnancy
Prednisone or Hydrocortisone use in last 24 hours
Intervention: Cladribine
Trial phase: Phase 4
ATC code: L01BB04 | L04AA40
SMILES: Nc1nc(Cl)nc2c1ncn2[C@H]1C[C@H](O)[C@@H](CO)O1
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 482
Group description: Participants with Relapsing Multiple Sclerosis (RMS) received Mavenclad® 3.5 milligram per kilogram (mg/kg) of body weight over 2 years, administered as 1 treatment course of 1.75 mg/kg per year. Each treatment course consisted of 2 treatment weeks, one at the beginning of the first month and one at the beginning of the second month of the respective year.
Eligibility criteria:
Inclusion Criteria:

Highly active RMS as defined by:
One relapse in the previous year and at least 1 T1 Gadolinium (Gd)+ lesion or 9 or more T2 lesions, while on therapy with other disease modifying drugs (DMDs).
Two or more relapses in the previous year, whether on DMD treatment or not.
Expanded Disability Status Scale (EDSS) score less than equals to (<=) 5.0.
Other protocol defined inclusion criteria could apply.

Exclusion Criteria:

Positive hepatitis C or hepatitis B surface antigen test and/or core antibody test for immunoglobulin G (IgG) and/or immunoglobulin M (IgM).
Current or previous history of immune deficiency disorders including a positive human immunodeficiency virus (HIV) result.
Currently receiving immunosuppressive or myelosuppressive therapy with, for example, monoclonal antibodies, methotrexate, cyclophosphamide, cyclosporine or azathioprine, or chronic use of corticosteroids.
History of tuberculosis, presence of active tuberculosis, or latent tuberculosis
Presence of Progressive Multifocal Leukoencephalopathy (PML) in Magnetic Resonance Imaging (MRI).
Active malignancy.
Other protocol defined exclusion criteria could apply.
Intervention: Minocycline
Trial phase: Phase 4
ATC code: A01AB23 | D10AF07 | J01AA08 | J01AA20
SMILES: [H][C@@]12Cc3c(N(C)C)ccc(O)c3C(=O)C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@]1([H])C2
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 57
Group description: 200 mg minocycline hydrochloride IV infusion over approximately 60 minutes

Minocycline: Minocycline is a semisynthetic derivative of tetracycline and is indicated for the treatment of infections due to susceptible isolates of designated microorganisms.
Eligibility criteria:
Inclusion Criteria:

Male or female > / = 18 years of age.
Subject is in the ICU, or is being admitted to the ICU.
Known or suspected Gram-negative infection for which the subject is receiving systemic antibiotics, and which was the reason for admission to the ICU, or reason for persistent need for ICU care.
Expectation, in the judgment of the investigator, that the subject will remain admitted in the hospital for at least 48 hours following enrollment and that all study procedures will be completed.
Expectation that intravenous access will be sufficient for drug infusion and either intravenous or arterial access will be sufficient to allow for all protocol required blood sampling to occur.
The subject, or legally authorized representative (LAR), is able and willing to provide signed informed consent.

Exclusion Criteria:

History of significant hypersensitivity or allergic reaction to tetracycline antibiotics.
Receipt of oral or intravenous tetracycline class drugs within 7 days of enrollment (e.g., minocycline, tetracycline, tigecycline, doxycycline).
Use of isotretinoin within 2 weeks of enrollment into the study.

Major surgery* within 48 hours prior to enrollment.

*Major surgery is defined as "the opening of either a body cavity or the mesenchymal barrier, using general anesthesia".

Pregnant or breastfeeding women.
Patient is being treated for intracranial hypertension.

Any condition that, in the judgment of the investigator, precludes participation because it could affect subject safety.*

*Subjects on, or who may be considered for Renal Replacement Therapy (RRT) during the study period are not excluded from participating in the study.

Receipt of an investigational study product within 7 days prior to enrollment. Investigator discretion should be used when longer acting agents have been used in the previous 30 days.